Should Mazor Robotics’ Investors Fear the Incoming Competition?

(The Motley Fool) – Many industry experts believe that the robotic surgery market is on the cusp of a dramatic expansion. For example, a recent report from predicts that the market will grow from $4.9 billion in 2016 to nearly $13 billion by 2021. Naturally, a market of that size has attracted the attention of several companies that want to get in on the action.

However, only a few companies have succeeded in bringing a robotic surgery system to market thus far. Mazor Robotics (NASDAQ:MZOR) is one of those few businesses. The company currently boasts two surgical systems for sale — the Renaissance and Mazor X — both of which help surgeons perform spine and brain procedures. With a worldwide install base of more than 150 systems, Mazor has established itself as the lead husky in its field. But with lots of competition on the way, should investors be fearful?

The competition

Your first instinct might be to assume that Intuitive Surgical (NASDAQ:ISRG) is the company’s main opponent, since it is the pioneer in the use of robots during surgery. However, Intuitive’s da Vinci is primarily designed for use in gynecological, urological, and general surgery procedures, not procedures involving bones. Since Mazor’s products are exclusively focused on fixing problems with the spine and brain, there actually isn’t any direct competition between the two — at least not yet.

Instead of Intuitive, Mazor’s investors need to keep their eyes trained on companies like Zimmer Biomet Holdings (NYSE:ZBH) and Globus Medical (NYSE:GMED), both of which are focused on developing robotic products that could be used for spine and brain surgeries. That’s a much more direct competitive threat.

Zimmer Biomet, in particular, made a big move into the space last year through its acquisition of MedTech SA. Medtech was the original developer of the ROSA robot, which is a robotic arm that has received regulatory approval in both the U.S. and EU for spine and brain surgeries. Just like Mazor’s products, ROSA is designed to help surgeons increase their accuracy and precision with screw and implant placement. So far, a few dozen ROSA systems have been sold and are actively being used.

By Brian Feroldi  | The Motley Fool

Image Credit: Mazor Robotics


About Peter Coffaro 818 Articles
A growth-driven and strategic executive, Peter Coffaro commands more than 20 years of progressive management success within the orthopedic industry. Recognized by as one of the top medical sales influencers in the industry; he has 10 years of combined sales management experience and has held positions as a Director, General Manager and Distributor. Peter has worked for some of the top orthopedic companies in the world - Zimmer, DePuy and Stryker. He is also the founder of OrthoFeed: a popular blog that covers orthopedic news and emerging medical technologies. Peter is a three-time Hall of Fame award winner at Johnson and Johnson and has an extensive background in organizational development, business development, sales management, digital marketing and professional education. Peter holds a B.S. degree in Biology from Northern Illinois University.

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.